Cell-penetrating peptides in protein mimicry and cancer therapeutics
- PMID: 34774552
- DOI: 10.1016/j.addr.2021.114044
Cell-penetrating peptides in protein mimicry and cancer therapeutics
Erratum in
-
Corrigendum to 'Cell-penetrating peptides in protein mimicry and cancer therapeutics' [Advanced Drug Delivery Reviews, 180 (2022), 114044].Adv Drug Deliv Rev. 2022 Mar;182:114128. doi: 10.1016/j.addr.2022.114128. Epub 2022 Jan 20. Adv Drug Deliv Rev. 2022. PMID: 35067369 No abstract available.
Abstract
Extensive research has been undertaken in the pursuit of anticancer therapeutics. Many anticancer drugs require specificity of delivery to cancer cells, whilst sparing healthy tissue. Cell-penetrating peptides (CPPs), now well established as facilitators of intracellular delivery, have in recent years advanced to incorporate target specificity and thus possess great potential for the targeted delivery of anticancer cargoes. Though none have yet been approved for clinical use, this novel technology has already entered clinical trials. In this review we present CPPs, discuss their classification, mechanisms of cargo internalization and highlight strategies for conjugation to anticancer moieties including their incorporation into therapeutic proteins. As the mainstay of this review, strategies to build specificity into tumor targeting CPP constructs through exploitation of the tumor microenvironment and the use of tumor homing peptides are discussed, whilst acknowledging the extensive contribution made by CPP constructs to target specific protein-protein interactions integral to intracellular signaling pathways associated with tumor cell survival and progression. Finally, antibody/antigen CPP conjugates and their potential roles in cancer immunotherapy and diagnostics are considered. In summary, this review aims to harness the potential of CPP-aided drug delivery for future cancer therapies and diagnostics whilst highlighting some of the most recent achievements in selective delivery of anticancer drugs, including cytostatic drugs, to a range of tumor cells both in vitro and in vivo.
Keywords: Cancer cell targeting; Cancer therapy and diagnostics; Cell-penetrating peptides; Intracellular signaling; Protein mimics.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
